14th International Conference on Generic Drugs and Biosimilars

14th International Conference on

Generic Drugs and Biosimilars

November 15-16, 2018 | Berlin, Germany

Best Western Premier Airporthotel Fontane Berlin

Theme: A new Era in Biosimilars Industry –Biosimilars & Generics         

Home | Conference Brochure | Submit Abstract | Scientific Sessions

Conference series takes pleasure in inviting the scientific community across the globe to attend the 14th International Conference on Generic Drugs & Biosimilars during November 15-16, 2018 at Berlin, Germany with a motto to Explore Innovations in Biosimilars, Biologics, Generic drugs, Pharmaceutical Sciences, Pharma Industry, Drug delivery & Drug discovery.

The gathering will address Pharmaceutical & Biosimilar Research in the area of Pharmaceutical manufacturing, while laying emphasis on innovative methodologies in pharmaceutical and food manufacturing.  Generic Biosimilars 2018 will be the best venue for Research Associate, Research Scientist, Directors, CEO’s of Pharmaceutical & Biosimilars Organizations, Drug Delivery Technology Manufacturers, Regulatory Affairs Associate, Bio Statistician, Health professionals, Scholars from Pharmaceutical backgrounds, Quality Control Analyst, Quality Assurance Specialist, Market research Analyst, Associate Product Manager, Product Manager, Strategy Director, Business Development Manager, Pharmacists, Deans, Students, Professors, Researchers, and Faculty of Pharmaceutical Sciences from Universities and Medical Colleges.

Keynote Speech: 1)The End of Phase 3 Clinical Trials in Biosimilars Development?

Francois-Xavier Frapaise, Principal, FX Frapaise Consulting, France

2)The importance of ensuring a sustainable market for Biosimilars

Erin Federman, Head of Biologics, Europe at Mylan

3)Workshop on: Biosimilars: Patient-Centricity

Francois-Xavier Frapaise, Principal, FX Frapaise Consulting, France

4)Pannel discussion on:

- Experience of Patient Advisory Boards

- Role of patients in protocol optimization ( ensuring the study protocols are feasible from a patient perspective)

- Patients Assistance Programs

- Patients education on Biosimilars

Francois-Xavier Frapaise, Principal, FX Frapaise Consulting, France
 

Previous Speakers:

Volkmar Weissig, Nanomedicine Center of Excellence in Translational Cancer Research, USA; Angela van der Salm, Director DADA Consultancy B.V, Netherlands; Patrizia Chetoni, University of Pisa, Italy; Christopher Tirotta, Director Cardiac Anesthesia, USA; Victoria Sherwood, University of Dundee, UK; Pierre A. Morgon, MRGN Advisors, Switzerland; Steve Hood, Director, Bioimaging, UK; Shelley Gandhi, Director NDA Group AB, UK; Hyungil Jung, Yonsei University, South Korea; Steve Rannard, University of Liverpool, UK; Achim Aigner, Leipzig University, Germany; Fiorenza Rancan, Universitätsmedizin Berlin, Germany; Balint Sinko, Pion Inc., USA; Christine Dufès, University of Strathclyde, UK; Flavia Laffleur, University of Innsbruck, Austria; Serena Mazzucchelli, University of Milan, Italy.

Generic Biosimilars 2018 Conference will encourage Young Researcher’s Forum, scientists and the researchers in their early stage of career graph to widely discuss their outcome so as to enrich and develop the idea. The ‘Best Poster Award’ is meant to encourage students in taking active part in the International Science platform to sharpen their skills and knowledgebase.

The important tracks that are part of Generic Biosimilars 2018 includes Generic Drugs, Generic Pills and Generic Medication, Biologics & Biosimilars, Pharmacovigilance & Safety of Biosimilars, Biosimilars Uptake & Patient Safety, Developing Biosimilars And Biobetters, Protein Biotherapeutics & biosimilars, Chronicles of a Biosimilar Production Facility , Biosimilar development challenges, Pharmacology and Drug Developement, Case Study Mitigating Risk in Biosimilar Development, Quality Control / R & D, Array of Clinical Trials in Biosimilars, Patent Access & Intellectual property & FDA Regulations, Pharma Pricing & Market Access, Licensing, Manufacturing& Health Economics, Generics & Biosimilars Industry Strategy, Global Generic Trends & Global Pharma Market, Innovation & Technology for Biosimilar Development, Biosimilars Differentiated Through Novel Drug Delivery Technologies, GMP, GCP and Quality Control, Office of Generic Drugs (OGD), Entrepreneurs Investment Meet.

Generic Biosimilars 2018 is comprised of 22 tracks and 110 sessions designed to offer comprehensive sessions that address current issue. For more scientific sessions and abstract submission, please visit:

https://generic-market.pharmaceuticalconferences.com/

The Abstracts that are accepted for presentations are published in the proceedings of the Journals like Journal of Developing Drugs, Drug Designing: Open Access and Journal of Bioequivalence & Bioavailability.

Grab the opportunity to participate by registering through flowing link:

https://generic-market.pharmaceuticalconferences.com/registration.php

For further details, please contact:

Regards
Missy Christen | Program Manager

Generic Biosimilars 2018
47 Churchfield Road
London, W3 6AY, UK
Direct: (702) 508-5200 Ext: 8028
E: [email protected]